Discovery of γ-Tetrahydrocarboline Derivatives as Plasmodium falciparum Histone Deacetylase Inhibitors for Treatment of Malaria
Authors:
- 4 January 2026
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
Abstract
Malaria is a life-threatening infectious disease caused by Plasmodium parasites, and the emergence of widespread resistance to existing therapies underscores the urgent need for novel antimalarial agents. Quisinostat was identified as a Plasmodium falciparum histone deacetylase 1 (PfHDAC1) inhibitor against drug-resistant malaria parasites but suffered from intolerable toxicity. To achieve a potent and safe antimalarial agent, we hypothesized a scaffold hopping and linker optimization strategy, in which a total of 33 new structural γ-tetrahydrocarboline derivatives were synthesized and subjected to comprehensive evaluation. Compound 5ac was identified as a PfHDAC1 inhibitor with favorable safety profiles (Pf3D7 IC50 = 4.1 nM, HepG2 IC50 = 1.5 μM, SI = 358; HEK293T IC50 = 15 μM, SI = 3573), improved physicochemical properties, and potent in vivo antimalarial activity. Mechanistic studies showed that 5ac could downregulate the expression of malaria invasion-related genes. Overall, this study establishes γ-tetrahydrocarboline derivatives as new structurally promising PfHDAC-targeted antimalarial agents.Keywords
Funding Information
- National Program for Support of Top-notch Young Professionals
- Youth Innovation Promotion Association of the Chinese Academy of Sciences (2023290)
- National Natural Science Foundation of China (22277106)
- National Natural Science Foundation of China (82025023)
- National Natural Science Foundation of China (82202551)
- National Natural Science Foundation of China (82230079)
- National Natural Science Foundation of China (82272363)
- National Natural Science Foundation of China (U24A20801)
- Zhejiang Provincial Outstanding Youth Science Foundation (LR23H300001)
This publication has 38 references indexed in Scilit:
- Design, synthesis and therapeutic evaluation of novel antimalarial derivatives based on the clinical antitumor candidate drug QuisinostatBioorganic & Medicinal Chemistry, 2024
- MalariaThe Lancet, 2023
- Chemical proteomic profiling with photoaffinity labeling strategy identifies antimalarial targets of artemisininChinese Chemical Letters, 2023
- Design, synthesis, and biological evaluation of multiple targeting antimalarialsActa Pharmaceutica Sinica B, 2021
- Repurposing of antitumor drug candidate Quisinostat lead to novel spirocyclic antimalarial agentsChinese Chemical Letters, 2021
- A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype–genotype association studyThe Lancet Infectious Diseases, 2017
- A Plasmodium falciparum Histone Deacetylase Regulates Antigenic Variation and Gametocyte ConversionCell Host & Microbe, 2014
- Acetylation and deacetylation of non-histone proteinsGene, 2005
- Anti-malarial effect of histone deacetylation inhibitors and mammalian tumour cytodifferentiating agentsInternational Journal for Parasitology, 2000
- Molecular cloning and nuclear localization of a histone deacetylase homologue in Plasmodium falciparumMolecular and Biochemical Parasitology, 1999